Drug intelligence / Profile preview

lenalidomide + dexamethasone + MEDI-551

Development stage: Unknown
Lead developer: Bristol Myers Squibb
Modality: Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Oral, Intravenous

Overview

This combination involves **lenalidomide**, a structural analogue of thalidomide used in treating multiple myeloma; **dexamethasone**, a corticosteroid; and **MEDI-551**, a monoclonal antibody targeting CD19. Lenalidomide works by modulating the immune system and inhibiting angiogenesis. Dexamethasone is used for its anti-inflammatory and immunosuppressive effects. MEDI-551 depletes B cells by targeting CD19, which may be beneficial in reducing cancer stem cells in multiple myeloma.

Targets

GR (Glucocorticoid receptor)CD19 (B lymphocyte antigen CD19)CRBN (Cereblon)

Beyond the preview

Go deeper on lenalidomide + dexamethasone + MEDI-551.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on lenalidomide + dexamethasone + MEDI-551.

Explore the full profile